Amycretin (zenagamtide)
Metabolic Health · GLP-1 / amylin co-agonist
Tier B-
Bottom line
Read Off Label grades Amycretin (zenagamtide) as B- (5.9/10) based on moderate evidence, high benefit magnitude, and a med-risk safety profile.
Novo Nordisk next-generation incretin (development name zenagamtide).
Studied, labeled, or reported-use context: SC once weekly or oral once daily; Phase 2 doses titrated — Investigational; not individualized guidance.
What the evidence says
Novo Nordisk next-generation incretin (development name zenagamtide). Phase 2 in type 2 diabetes presented at ADA 2026: up to 14.5% weight loss at 36 weeks (SC ~11.9% and oral ~7.6% placebo-adjusted), up to ~89% reaching HbA1c <7%, mostly mild GI side effects. Phase 3 program planned H2 2026. Industry-sponsored; peer-reviewed publication pending.
Mechanism
Unimolecular co-agonist of the GLP-1 and amylin receptors, available in both oral and subcutaneous forms, pairing incretin appetite suppression with amylin-mediated satiety in one molecule.
Studied, labeled, or reported dose & route
SC once weekly or oral once daily; Phase 2 doses titrated
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Amycretin (zenagamtide)'s effects?
- Read Off Label rates the evidence for Amycretin (zenagamtide) as Moderate and the benefit magnitude as high, producing an overall grade of B- (5.9/10). Novo Nordisk next-generation incretin (development name zenagamtide).
- What safety findings are reported for Amycretin (zenagamtide)?
- Amycretin (zenagamtide) has a med risk profile in the database. Med (dose-dependent GI: nausea, vomiting) Legal status: Investigational (Phase 3 initiated Q1 2026).
- What doses or routes are reported for Amycretin (zenagamtide)?
- SC once weekly or oral once daily; Phase 2 doses titrated This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Amycretin (zenagamtide) work?
- Unimolecular co-agonist of the GLP-1 and amylin receptors, available in both oral and subcutaneous forms, pairing incretin appetite suppression with amylin-mediated satiety in one molecule.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.